Clinico-pathological  ||| S:0 E:21 ||| NNP
and  ||| S:21 E:25 ||| CC
molecular  ||| S:25 E:35 ||| JJ
subtypes  ||| S:35 E:44 ||| NN
of  ||| S:44 E:47 ||| IN
male  ||| S:47 E:52 ||| JJ
breast  ||| S:52 E:59 ||| NN
carcinoma  ||| S:59 E:69 ||| VBZ
according  ||| S:69 E:79 ||| VBG
to  ||| S:79 E:82 ||| TO
immunohistochemistry  ||| S:82 E:103 ||| VB
Male  ||| S:103 E:108 ||| JJ
breast  ||| S:108 E:115 ||| NN
carcinoma  ||| S:115 E:125 ||| NN
is  ||| S:125 E:128 ||| VBZ
a  ||| S:128 E:130 ||| DT
rare  ||| S:130 E:135 ||| JJ
condition ||| S:135 E:144 ||| NN
,  ||| S:144 E:146 ||| ,
but  ||| S:146 E:150 ||| CC
with  ||| S:150 E:155 ||| IN
a  ||| S:155 E:157 ||| DT
trend  ||| S:157 E:163 ||| NN
of  ||| S:163 E:166 ||| IN
increase  ||| S:166 E:175 ||| NN
frequency ||| S:175 E:184 ||| NN
.  ||| S:184 E:186 ||| .
In  ||| S:186 E:189 ||| IN
our  ||| S:189 E:193 ||| PRP$
study ||| S:193 E:198 ||| NN
,  ||| S:198 E:200 ||| ,
we  ||| S:200 E:203 ||| PRP
investigate  ||| S:203 E:215 ||| VB
the  ||| S:215 E:219 ||| DT
clinico-pathological  ||| S:219 E:240 ||| JJ
features  ||| S:240 E:249 ||| NNS
and  ||| S:249 E:253 ||| CC
overall  ||| S:253 E:261 ||| JJ
survival  ||| S:261 E:270 ||| NN
at  ||| S:270 E:273 ||| IN
35  ||| S:273 E:276 ||| CD
male  ||| S:276 E:281 ||| JJ
cases  ||| S:281 E:287 ||| NNS
of  ||| S:287 E:290 ||| IN
primary  ||| S:290 E:298 ||| JJ
invasive  ||| S:298 E:307 ||| JJ
breast  ||| S:307 E:314 ||| NN
carcinoma  ||| S:314 E:324 ||| NN
correlated  ||| S:324 E:335 ||| NN
with  ||| S:335 E:340 ||| IN
molecular  ||| S:340 E:350 ||| JJ
subtypes  ||| S:350 E:359 ||| NNS
defined  ||| S:359 E:367 ||| VBN
by  ||| S:367 E:370 ||| IN
immunohistochemical  ||| S:370 E:390 ||| JJ
profile ||| S:390 E:397 ||| NN
.  ||| S:397 E:399 ||| .
Based  ||| S:399 E:405 ||| VBN
on  ||| S:405 E:408 ||| IN
immunohistochemical  ||| S:408 E:428 ||| JJ
expression  ||| S:428 E:439 ||| NN
profiles  ||| S:439 E:448 ||| NNS
of  ||| S:448 E:451 ||| IN
estrogen  ||| S:451 E:460 ||| JJ
receptor  ||| S:460 E:469 ||| NN
( ||| S:469 E:470 ||| -LRB-
ER ||| S:470 E:472 ||| NNP
) ||| S:472 E:473 ||| -RRB-
,  ||| S:473 E:475 ||| ,
progesterone  ||| S:475 E:488 ||| JJ
receptor  ||| S:488 E:497 ||| NN
( ||| S:497 E:498 ||| -LRB-
PR ||| S:498 E:500 ||| NNP
) ||| S:500 E:501 ||| -RRB-
,  ||| S:501 E:503 ||| ,
human  ||| S:503 E:509 ||| JJ
epidermal  ||| S:509 E:519 ||| JJ
growth  ||| S:519 E:526 ||| NN
factor  ||| S:526 E:533 ||| NN
2  ||| S:533 E:535 ||| CD
( ||| S:535 E:536 ||| -LRB-
HER2 ||| S:536 E:540 ||| NNP
)  ||| S:540 E:542 ||| -RRB-
and  ||| S:542 E:546 ||| CC
Ki67 ||| S:546 E:550 ||| NNP
,  ||| S:550 E:552 ||| ,
EGFR  ||| S:552 E:557 ||| NNP
and  ||| S:557 E:561 ||| CC
CK5 ||| S:561 E:564 ||| CD
/ ||| S:564 E:565 ||| CD
6 ||| S:565 E:566 ||| CD
,  ||| S:566 E:568 ||| ,
the  ||| S:568 E:572 ||| DT
male  ||| S:572 E:577 ||| JJ
breast  ||| S:577 E:584 ||| NN
cancers  ||| S:584 E:592 ||| NNS
were  ||| S:592 E:597 ||| VBD
classified  ||| S:597 E:608 ||| VBN
into  ||| S:608 E:613 ||| IN
the  ||| S:613 E:617 ||| DT
following  ||| S:617 E:627 ||| JJ
molecular  ||| S:627 E:637 ||| JJ
subtypes ||| S:637 E:645 ||| NN
:  ||| S:645 E:647 ||| :
Luminal  ||| S:647 E:655 ||| NNP
A ||| S:655 E:656 ||| NNP
,  ||| S:656 E:658 ||| ,
Luminal  ||| S:658 E:666 ||| NNP
B ||| S:666 E:667 ||| NNP
,  ||| S:667 E:669 ||| ,
HER2+ ||| S:669 E:674 ||| NNP
,  ||| S:674 E:676 ||| ,
triple  ||| S:676 E:683 ||| RB
negative  ||| S:683 E:692 ||| JJ
and  ||| S:692 E:696 ||| CC
unclassified ||| S:696 E:708 ||| JJ
.  ||| S:708 E:710 ||| .
In  ||| S:710 E:713 ||| IN
our  ||| S:713 E:717 ||| PRP$
study ||| S:717 E:722 ||| NN
,  ||| S:722 E:724 ||| ,
we  ||| S:724 E:727 ||| PRP
identified  ||| S:727 E:738 ||| VBD
65.7 ||| S:738 E:742 ||| CD
%  ||| S:742 E:744 ||| NN
as  ||| S:744 E:747 ||| IN
Luminal  ||| S:747 E:755 ||| NNP
A  ||| S:755 E:757 ||| DT
subtype  ||| S:757 E:765 ||| NN
and  ||| S:765 E:769 ||| CC
28.6 ||| S:769 E:773 ||| CD
%  ||| S:773 E:775 ||| NN
as  ||| S:775 E:778 ||| IN
Luminal  ||| S:778 E:786 ||| NNP
B  ||| S:786 E:788 ||| NNP
subtype ||| S:788 E:795 ||| NN
.  ||| S:795 E:797 ||| .
The  ||| S:797 E:801 ||| DT
difference  ||| S:801 E:812 ||| NN
was  ||| S:812 E:816 ||| VBD
represented  ||| S:816 E:828 ||| VBN
by  ||| S:828 E:831 ||| IN
two  ||| S:831 E:835 ||| CD
( ||| S:835 E:836 ||| -LRB-
5.7 ||| S:836 E:839 ||| CD
% ||| S:839 E:840 ||| NN
)  ||| S:840 E:842 ||| -RRB-
cases  ||| S:842 E:848 ||| NNS
of  ||| S:848 E:851 ||| IN
triple  ||| S:851 E:858 ||| JJ
negative  ||| S:858 E:867 ||| JJ
subtype ||| S:867 E:874 ||| NN
,  ||| S:874 E:876 ||| ,
but  ||| S:876 E:880 ||| CC
due  ||| S:880 E:884 ||| JJ
to  ||| S:884 E:887 ||| TO
low  ||| S:887 E:891 ||| JJ
number  ||| S:891 E:898 ||| NN
of  ||| S:898 E:901 ||| IN
patients ||| S:901 E:909 ||| NNS
,  ||| S:909 E:911 ||| ,
no  ||| S:911 E:914 ||| DT
correlations  ||| S:914 E:927 ||| NN
or  ||| S:927 E:930 ||| CC
prognostic  ||| S:930 E:941 ||| JJ
significance  ||| S:941 E:954 ||| NN
could  ||| S:954 E:960 ||| MD
be  ||| S:960 E:963 ||| VB
assessed  ||| S:963 E:972 ||| VBN
in  ||| S:972 E:975 ||| IN
these  ||| S:975 E:981 ||| DT
cases ||| S:981 E:986 ||| NNS
.  ||| S:986 E:988 ||| .
No  ||| S:988 E:991 ||| DT
HER2  ||| S:991 E:996 ||| NNP
or  ||| S:996 E:999 ||| CC
unclassified  ||| S:999 E:1012 ||| JJ
subtypes  ||| S:1012 E:1021 ||| NN
were  ||| S:1021 E:1026 ||| VBD
identified ||| S:1026 E:1036 ||| VBN
.  ||| S:1036 E:1038 ||| .
Luminal  ||| S:1038 E:1046 ||| VBG
A  ||| S:1046 E:1048 ||| DT
tumors  ||| S:1048 E:1055 ||| NNS
are  ||| S:1055 E:1059 ||| VBP
the  ||| S:1059 E:1063 ||| DT
most  ||| S:1063 E:1068 ||| RBS
frequent  ||| S:1068 E:1077 ||| JJ
subtype  ||| S:1077 E:1085 ||| NN
in  ||| S:1085 E:1088 ||| IN
MBC ||| S:1088 E:1091 ||| NNP
,  ||| S:1091 E:1093 ||| ,
with  ||| S:1093 E:1098 ||| IN
a  ||| S:1098 E:1100 ||| DT
better  ||| S:1100 E:1107 ||| JJR
outcome  ||| S:1107 E:1115 ||| NN
than  ||| S:1115 E:1120 ||| IN
Luminal  ||| S:1120 E:1128 ||| NNP
B  ||| S:1128 E:1130 ||| NNP
subtype ||| S:1130 E:1137 ||| NN
.  ||| S:1137 E:1139 ||| .
We  ||| S:1139 E:1142 ||| PRP
recorded  ||| S:1142 E:1151 ||| VBD
high  ||| S:1151 E:1156 ||| JJ
levels  ||| S:1156 E:1163 ||| NNS
of  ||| S:1163 E:1166 ||| IN
ER  ||| S:1166 E:1169 ||| NNP
and  ||| S:1169 E:1173 ||| CC
PR  ||| S:1173 E:1176 ||| NNP
expression ||| S:1176 E:1186 ||| NN
,  ||| S:1186 E:1188 ||| ,
which  ||| S:1188 E:1194 ||| WDT
predict  ||| S:1194 E:1202 ||| VBP
a  ||| S:1202 E:1204 ||| DT
better  ||| S:1204 E:1211 ||| JJR
response  ||| S:1211 E:1220 ||| NN
to  ||| S:1220 E:1223 ||| TO
adjuvant  ||| S:1223 E:1232 ||| VB
hormonal  ||| S:1232 E:1241 ||| JJ
therapy ||| S:1241 E:1248 ||| NN
.  ||| S:1248 E:1250 ||| .
At  ||| S:1250 E:1253 ||| IN
the  ||| S:1253 E:1257 ||| DT
time  ||| S:1257 E:1262 ||| NN
of  ||| S:1262 E:1265 ||| IN
diagnosis ||| S:1265 E:1274 ||| NN
,  ||| S:1274 E:1276 ||| ,
most  ||| S:1276 E:1281 ||| JJS
of  ||| S:1281 E:1284 ||| IN
the  ||| S:1284 E:1288 ||| DT
patients  ||| S:1288 E:1297 ||| NNS
were  ||| S:1297 E:1302 ||| VBD
aged  ||| S:1302 E:1307 ||| VBN
and  ||| S:1307 E:1311 ||| CC
with  ||| S:1311 E:1316 ||| IN
an  ||| S:1316 E:1319 ||| DT
advance  ||| S:1319 E:1327 ||| NN
clinical  ||| S:1327 E:1336 ||| JJ
stage ||| S:1336 E:1341 ||| NN
,  ||| S:1341 E:1343 ||| ,
this  ||| S:1343 E:1348 ||| DT
requiring  ||| S:1348 E:1358 ||| VBG
implementation  ||| S:1358 E:1373 ||| NN
of  ||| S:1373 E:1376 ||| IN
screening  ||| S:1376 E:1386 ||| VBG
programs  ||| S:1386 E:1395 ||| NNS
and  ||| S:1395 E:1399 ||| CC
increase  ||| S:1399 E:1408 ||| NN
education  ||| S:1408 E:1418 ||| NN
of  ||| S:1418 E:1421 ||| IN
population  ||| S:1421 E:1432 ||| NN
in  ||| S:1432 E:1435 ||| IN
order  ||| S:1435 E:1441 ||| NN
to  ||| S:1441 E:1444 ||| TO
an  ||| S:1444 E:1447 ||| DT
early  ||| S:1447 E:1453 ||| JJ
detection ||| S:1453 E:1462 ||| NN
.  ||| S:1462 E:1464 ||| .
